Regencell Bioscience deals with struggling business, yet shares surge, WSJ says

Regencell Bioscience (RGC) is dealing with a struggling business and Justice Department investigation, yet shares have been surging, Jonathan Weil of The Wall Street Journal reports. The company claims it is developing traditional Chinese medicine to treat autism spectrum disorder and attention-deficit hyperactivity disorder. Despite recurring losses, no revenue, and no salable products, the company ended last week with a $15.5B stock-market value.